Drug Profile
Research programme: monoclonal antibody therapeutics - argenx/Bird Rock Bio
Alternative Names: Anti-Nav1.7 monoclonal antibody; Monoclonal antibodies targeting GPCR receptors - Bird Rock BioLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator arGEN-X
- Developer argenx; Bird Rock Bio
- Class Monoclonal antibodies
- Mechanism of Action G protein-coupled receptor modulators; Interleukin 6 inhibitors; Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Ovarian cancer; Pain; Renal cancer
Most Recent Events
- 18 Aug 2023 Bird Rock Bio has been acquired by Skye Bioscience
- 28 Mar 2020 No recent reports of development identified for preclinical development in Autoimmune-disorders in China (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)